Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

Sponsor
AbbVie
Study ID
NCT01768858
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen

Study Details

The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's disease (CD) and ulcerative colitis (UC) patients' adherence attitudes (beliefs) to maintenance therapy with adalimumab monotherapy or combination therapy with methotrexate (in participants with RA) and to investigate whether there were correlations between such beliefs and adherence to maintenance treatment.

Key Dates

Start date
Feb 5, 2013
Status verified
Jan 2019
Primary completion
Aug 13, 2017
Completion
Aug 13, 2017

Study Design

Enrollment
96 participants (actual)

Arms

  • Arm: Participants receiving adalimumab
    Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC) received 40 mg adalimumab every two weeks.

Primary Outcome Measure

Change From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months [ Time Frame: Baseline and 12 months ]

Related Studies